NEW YORK (GenomeWeb) – SEngine Precision Medicine has inked an exclusive licensing agreement with the Fred Hutchinson Cancer Research Center to market a diagnostic test designed to aid in the personalization of cancer treatments.

The assay, called PARIS, combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jun
05
Sponsored by
Linguamatics

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun
14
Sponsored by
Sophia Genetics

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.